Mastek Ltd Q1 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/ws5q26v9r7jyxkd893x9wfb2.pdf

Key Takeaways


UK & Europe: The Growth Engine

Abhishek Singh: "Now it is important to note that these cuts or these reductions would be achieved by higher digital spend or higher spend towards digitalizing the landscape that's already there and that's where Mastek is very well placed and positioned to make use of that and help the departments achieve that."

US: Bottoming Out, Rebuilding

Abhishek Singh: "The next $1 million or $2 million or $5 million or $10 million, if you look at it quarterly or annually, the revenue that comes in will contribute disproportionately to the bottom line."

Margins: Stable Now, Leverage Later

Abhishek Singh: "Do you continue to enjoy this profitability, albeit for a short time or do you invest in the organization to make it a robust organization for future?"

AI & Technology: Deployment as Differentiator

Abhishek Singh: "You are right that LLM is a commodity. Productivity is a given. Deployment will be the differentiator. Who deploys it best to deliver the outcomes that the clients require."

Strategic Initiatives & People

Abhishek Singh: "That geography forms the incubation of Mastek's Cerner Healthcare and Fusion capability intersection... His test cases will be in the Middle Eastern market, and then it will expand beyond in the APAC as much as Europe, UK and the US markets."

Guidance & Commitments

CommitmentSpecificsTimeline
Company-level EBITDA marginStable with a "stable to upward bias"FY26
US marginsReturn to near double-digit to low-double-digit operating EBITDA levels as revenue growsH2 FY26
UK marginsAspire to return to 23% levels, but a slow buildA few quarters
UK public sector renewalsTwo major engagements (health, secure government) to convert to longer renewals once budget approvals reach departmentsWhen spend review reaches departments
AMEA marginsBetter margin performance as bad debt provisions recoverNext quarters
US growthPositive bias and relative confidence to demonstrate growthH2 FY26
Order bookingEndeavor to deliver higher order booking to pave way for FY27 and FY28 growthOngoing
Double-digit growthAmbition remains, but Q1 started soft in non-UK geographies; 8 months remainFY26 (conditional)
Cerner healthcare initiativeTest cases in Middle Eastern market, then expand to APAC, Europe, UK, USNo date given
CFO appointmentWithin statutory timelines (90 days before penal zone)Per company law

Key Metrics

MetricQ1 FY26
Revenue₹915 cr, +12.5% YoY and +1% QoQ; constant currency decline of 1.1%
Total income growth13.2% YoY in rupee terms
Net profit₹92.1 cr, +28.7% YoY and +13.5% QoQ
Operating EBITDA margin15.0%, declined 31 bps QoQ
Operating EBITDA growth10.8% YoY
UK & Europe revenue growth27% YoY in reported currency and 8% QoQ
US revenue growthFlat YoY, 8.5% QoQ decline in dollar terms
AMEA revenue growthDeclined 16% YoY
AMEA segment profit declineDown nearly 48% YoY
North America segment margin2.9%, versus 12% last quarter
UK & Europe segment margin~19%, recovering toward prior 23% level
12-month order backlog₹27.4 cr, +3.5% QoQ and +5.5% YoY
US order book growth25% QoQ and YoY
Large deal TCV secured$15 million plus, in UK BFSI data transformation
Cash and cash equivalents₹549 cr, versus ₹622 cr last quarter
DSOs82 days, versus 83 days last quarter and 92 days last year same quarter
Headcount change~13% reduction YoY and ~5% QoQ
Voluntary attritionNot stated as a specific figure in the transcript